Clover Health Investments Corp

CLOV has posted a decisive momentum breakout above the consolidation high with volume and EMAs aligned, but price is extended and RSI is overbought. In a Stage 2 advancing structure, medium-term bias remains bullish. We defer execution and await a shallow pullback into the rising 9- and 20-EMA near the $4.45–$4.60 support zone before participating in line with the Momentum + EPS strategy.

• ↑Q2 revenue $743.2M (+55.6% YoY) and EPS $0.05 beats estimates.
• ↑GAAP net income $28M vs $11M loss year-ago; adj. EBITDA +139%.
• ↓Forward P/E of 82 signals high valuation risk.